Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Exacerbations - a general definition
- Severity of exacerbations of COPD
- Early therapy improves exacerbation outcome
- Treatment options for AECOPD
- Triggers of COPD exacerbations
- Etiology of AECOPD
- Role of bacteria in AECOPD
- Most common pathogens in COPD
- Pseudomonas aeruginosa in COPD
- Importance of bacterial & viral infections in COPD
- RSV detection and COPD
- Rhinovirus exposure impairs immune responses
- Discolored sputum associate with more bacteria
- Antibiotics and relapse rate association in AECB
- Relapse rate for selected antibiotic groups
- Use of antibiotics in mild form of exacerbations
- Therapies for AECB according to patient subsets
- COPD exacerbations: antibiotic therapy
- Comparison of first vs. second line antibiotics
- COPD exacerbation: antibiotics
- Bacterial eradication improves symptoms
- Moxifloxacin vs. macrolides
- Relation of strep. resistance and macrolide use
- Change in bacterial gene resistance
- Antibiotics and therapy duration
- Treatment failure in AECB
- Moxifloxacin increases time to composite event
- The ‘fall & rise’ of bacterial AECB
- Risk of pneumonia in AECOPD
- Systemic steroid vs. placebo in AECOPD
- Benefit of systemic steroid use in AECOPD
- Beta agonists
- Clinical case (1)
- Venturi mask
- Clinical case (2)
- Why is this patient more hypercapnic?
- Ventilator management
- COPD exacerbation: markers of severity
- Treatments improving survival
- Noninvasive ventilation (NIV)
- Noninvasive vs. conventional ventilation
- What are the contraindications for NIV
- Noninvasive positive pressure masks
- Ventilator settings
- Algorithm for NIV management
- Possible factors to consider in treatment failures
- Pulmonary rehabilitation after exacerbations
- COPD exacerbations: mortality
- COPD exacerbations: survival
- Conclusions
Topics Covered
- Treatment of COPD based on the underlying conditions
- The most important causes of COPD exacerbations: viral and bacterial infections
- Use of antibiotics in COPD
- Treatment of patients who develop respiratory failure
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Anzueto, A. (2022, January 23). Treatment of COPD exacerbations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 6, 2024, from https://doi.org/10.69645/VFQT8543.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Antonio Anzueto has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.